Skip to main content
Fig. 2 | Journal of Experimental & Clinical Cancer Research

Fig. 2

From: miRNA-106a directly targeting RARB associates with the expression of Na+/I symporter in thyroid cancer by regulating MAPK signaling pathway

Fig. 2

a, relative expression of miR-106a in CGTH-W3 and 8505C; b, miR-106a overexpression models [CGTH-W3- miR106a(+)]: CGTH-W3 cells transfected with lentiviral vectors carrying the miR-106a gene; c, miR-106a knockdown models [8505C-miR106a(−)]: 8505C cells transfected with miR-106a inhibitor gene; d, the seed structure of the 3′ UTR of RARB and the miR-106a binding site; e, results of dual-luciferase reporter assays; f, RARB mRNA expression in different management of cells detected by qRT-PCR; g, RARB protein expression in different management of cells by western blotting. (*, p < 0.01)

Back to article page